NLS Pharmaceutics Ltd. - Ordinary Shares (NQ:NLSP)

0.7620 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes

October 03, 2022

Via ACCESSWIRE

Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗

September 28, 2022

Gainers

Via Benzinga

NLS Pharmaceutics' Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors ↗

September 27, 2022

Via Benzinga

NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development

September 08, 2022

Via ACCESSWIRE

NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

September 27, 2022

Via ACCESSWIRE

NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results

September 19, 2022

Via ACCESSWIRE

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 06, 2022

Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Via InvestorPlace

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release

July 28, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

From NLS Pharmaceutics AG

Via AccessWire

Topics Intellectual Property

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release

July 28, 2022

Via ACCESSWIRE

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 22, 2022

Good morning! We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday!

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 ↗

September 06, 2022

Upgrades

Via Benzinga

Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket ↗

July 22, 2022

Gainers

Via Benzinga

Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday ↗

August 24, 2022

Gainers

Via Benzinga

NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

July 21, 2022

Via ACCESSWIRE

Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session ↗

August 23, 2022

Gainers

Via Benzinga

NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

July 21, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

From NLS Pharmaceutics AG

Via AccessWire

Stocks That Hit 52-Week Lows On Monday ↗

July 25, 2022

On Monday, 100 companies reached new 52-week lows.

Via Benzinga

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday ↗

July 25, 2022

Gainers

Via Benzinga

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

June 10, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

From NLS Pharmaceutics AG

Via AccessWire

This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

July 22, 2022

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.

Via Benzinga

NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer

June 06, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

From NLS Pharmaceutics AG

Via AccessWire

Topics Bankruptcy Initial Public Offering

This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday ↗

July 22, 2022

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...

Via Benzinga

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy

June 02, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

From NLS Pharmaceutics AG

Via AccessWire

NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

May 04, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From NLS Pharmaceutics AG

Via AccessWire

Topics Intellectual Property

NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering

April 26, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

From NLS Pharmaceutics AG

Via AccessWire

Topics Regulatory Compliance

NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference

April 22, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

From NLS Pharmaceutics AG

Via AccessWire

NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 13, 2022

ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

From NLS Pharmaceutics AG

Via AccessWire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.